Work

A Phase I/II Study of Intravenous LBH589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Patients (pts) with Advanced Hematologic Malignancies.

Year: 2004

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v104.11.1802.1802

Authors: Francis J. Giles, Thomas Fischer, Jorge Cortes, James Beck, Farhad Ravandi-Kashani, Guillermo Garcia-Manero, Hagop M. Kantarjian, Bin Peng, Patricia E. Rae, Glen Laird, Samil Sharma, Margaret Dugan, Maher Albitar, Kapil M. Bhalla

Institutions: The University of Texas MD Anderson Cancer Center, Johannes Gutenberg University Mainz, Quest Diagnostics (United States), Moffitt Cancer Center

Language: English

Topic: Histone Deacetylase Inhibitors Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2550109795

FWCI: 0.592

Cites:

Cited by: 5

Related to: 10